Lenalidomid Stada

Lenalidomide, the active ingredient in Lenalidomid Stada, is an immunomodulatory drug (IMiD) presented as an oral formulation for systemic use. Approved in the European Union, it is used to treat multiple myeloma, mantle cell lymphoma, and myelodysplastic syndromes with del(5q) in adult patients.

GNH USA supplies Lenalidomid Stada as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and regulatory compliance across multiple regions, including adherence to local import requirements and quality standards.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related bone marrow disorders. - Multiple myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. - Mantle cell lymphoma: induces tumor regression and prolongs remission when combined with standard chemotherapy. - Myelodysplastic syndromes with del(5q): corrects ineffective hematopoiesis and reduces transfusion dependence.

Lenalidomide may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels leading to bleeding tendencies. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require supportive care. - Rash: mild skin eruptions or itching.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophils with fever. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: elevated liver enzymes or liver injury. - Embryo‑fetal toxicity: high risk of birth defects if exposure occurs during pregnancy.

When prescribing Lenalidomide, clinicians should observe several safety precautions to minimize risks. - Pregnancy contraindication: drug is category X; avoid use in pregnant women and ensure effective contraception. - Thromboembolic risk: assess need for prophylactic anticoagulation in patients with additional risk factors. - Renal impairment: adjust monitoring and consider dose modification in patients with reduced kidney function. - Hematologic monitoring: perform regular complete blood counts to detect neutropenia or thrombocytopenia. - Drug interactions: review concomitant medications for potential major interactions. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce Lenalidomide exposure. - Anticoagulants (warfarin, direct oral anticoagulants): increased risk of bleeding when combined with thrombocytopenia.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may raise plasma levels modestly. - Immunosuppressants (e.g., cyclosporine): potential additive hematologic toxicity. - Hormonal contraceptives: reduced effectiveness; advise additional non‑hormonal methods.